CFTR involvement in nasal potential differences in mice and pigs studied using a thiazolidinone CFTR inhibitor

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 287, Issue 5 31-5, 2004, Pages

  Salinas, Danieli B ^a,b   Pedemonte, Nicoletta ^a,c   Muanprasat, Chatchai ^a   Finkbeiner, Walter F ^a   Nielson, Dennis W ^b   Verkman, A S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c G GASLINI INSTITUTE   (Italy)

Author keywords

Chloride channels; Cystic fibrosis; Cystic fibrosis transmembrane conductance regulator; Nasal potential difference

Indexed keywords

AMILORIDE; CHLORIDE; CHLORIDE CHANNEL; CYCLIC AMP; FORSKOLIN; GLIBENCLAMIDE; SODIUM CHLORIDE; TRANSMEMBRANE CONDUCTANCE REGULATOR; TRANSMEMBRANE CONDUCTANCE REGULATOR INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CHLORIDE CONDUCTANCE; CONTROLLED STUDY; CYSTIC FIBROSIS; DEPOLARIZATION; FEMALE; HYPERPOLARIZATION; MALE; MOUSE; NONHUMAN; POTENTIAL DIFFERENCE; PRIORITY JOURNAL; SHORT CIRCUIT CURRENT; SWINE;

4,4'-DIISOTHIOCYANOSTILBENE-2,2'-DISULFONIC ACID; AMILORIDE; ANIMALS; BENZOIC ACIDS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DIURETICS; FEMALE; FORSKOLIN; GLYBURIDE; HYPOGLYCEMIC AGENTS; MALE; MEMBRANE POTENTIALS; MICE; MICE, INBRED CFTR; NASAL MUCOSA; SUS SCROFA; THIAZOLES; THIAZOLIDINES;

EID: 6344250651     PISSN: 10400605     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajplung.00354.2003     Document Type: Article

References (32)

1. Ahrens RC, Standaert TA, Launspach J, Han SH, Teresi ME, Aitken ML, Kelley TJ, Billiard KA, Milgram LJ, Konstan MW, Weatherly MR, and McCarty NA. Use of nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis. Pediatr Pulmonol 33: 142-150, 2002.
2. Ballard ST, Trout L, Bebok Z, Sorscher EJ, and Crews A. CFTR involvement in chloride, bicarbonate, and liquid secretion by airway submucosal glands. Am J Physiol Lung Cell Mol Physiol 277: L694-L699, 1999.
3. Boyle MP, Diener-West M, Milgram L, Knowles M, Foy C, Zeitlin P, and Standaert T. A multicenter study of the effect of solution temperature on nasal potential difference measurements. Chest 124: 482-489, 2003.
4. Brady KG, Kelley TJ, and Drumm ML. Examining basal chloride transport using the nasal potential difference response in a murine model. Am J Physiol Lung Cell Mol Physiol 281: L1173-L1179, 2001.
5. + current by modification of a delayed rectifier channel in rat portal vein and insulinoma cells. Br J Pharmacol 110: 1280-1281, 1993.
6. Fajac I, Hubert D, Bienvenu T, Richaud-Thiriez B, Matran R, Kaplan JC, Dall'Ava-Santucci J, and Dusser DJ. Relationships between nasal potential difference and respiratory function in adults with cystic fibrosis. Eur Respir J 12: 1295-1300, 1998.
7. Fischer H, Fukuda N, Barbry P, Illek B, Sartori C, and Matthay M. Partial restoration of defective chloride conductance in ΔF508 CF mice by trimethylamine oxide. Am J Physiol Lung Cell Mol Physiol 281: L52-L57, 2001.
8. Ghosal S, Taylor CJ, Colledge WH, Ratcliff R, and Evans MJ. Sodium channel blockers and uridine triphosphate: effects on nasal potential difference in cystic fibrosis mice. Eur Respir J 15: 146-150, 2000.
9. - secretion in nasal epithelia of CF mice. Am J Physiol Cell Physiol 266: C1478-C1483, 1994.
10. Ho LP, Samways JM, Porteous DJ, Dorin JR, Carothers A, Greening AP, and Innes JA. Correlation between nasal potential difference measurements, genotype and clinical condition in patients with cystic fibrosis. Eur Respir J 10: 2018-2022, 1997.
11. Jiang C, Akita GY, Colledge WH, Ratcliff RA, Evans MJ, Hehir KM, St George JA, Wadsworth SC, and Cheng SH. Increased contact time improves adenovirus-mediated CFTR gene transfer to nasal epithelium of CF mice. Hum Gene Ther 8: 671-680, 1997.
12. Kelley TJ, Thomas K, Milgram LJ, and Drumm ML. In vivo activation of the cystic fibrosis transmembrane conductance regulator mutant ΔF508 in murine nasal epithelium. Proc Natl Acad Sci USA 94: 2604-2608, 1997.
13. Knowles M, Gatzy J, and Boucher R. Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis. N Engl J Med 305: 1489-1495, 1981.
14. Knowles M, Gatzy J, and Boucher R. Relative ion permeability of normal and cystic fibrosis nasal epithelium. J Clin Invest 71: 1410-1417, 1983.
15. Knowles M, Murray G, Shallal J, Askin F, Ranga V, Gatzy J, and Boucher R. Bioelectric properties and ion flow across excised human bronchi. J Appl Physiol 56: 868-877, 1984.
16. Knowles M, Paradiso AM, and Boucher R. In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum Gene Ther 6: 445-455, 1995.
17. Ma T, Thiagarajah JR, Yang H, Sonawane ND, Folli C, Galietta LJ, and Verkman AS. Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. J Clin Invest 110: 1651-1658, 2002.
18. Middleton PG, Geddes DM, and Alton EW. Protocols for in vivo measurement of the ion transport defects in cystic fibrosis nasal epithelium. Eur Respir J 7: 2050-2056, 1994.
19. - channel. Pflügers Arch 429: 659-662, 1995.
20. Ramjeesingh M, Huan LJ, Wilschanski M, Dune P, Li C, Gyomorey K, Wang Y, Kent G, Tanswell KA, Cutz E, Ackerley C, and Bear CE. Assessment of the efficacy of in vivo CFTR protein replacement therapy in CF mice. Hum Gene Ther 9: 521-528, 1998.
21. Sauder RA, Chesrown SE, and Loughlin GM. Clinical application of transepithelial potential difference measurements in cystic fibrosis. J Pediatr 111: 353-358, 1987.
22. Song Y, Thiagarajah JR, and Verkman AS. Ionic concentrations, pH and depth of airway surface liquid in distal airways. J Gen Physiol 122: 511-519, 2003.
23. Taddei A, Folli C, Zegarra-Moran O, Fanen P, Verkman AS, and Galietta LJ. Altered channel gating mechanism for CFTR inhibition by a high-affinity thiazolidinone blocker. FEBS Lett 558: 52-56, 2004.
24. Thiagarajah JR, Broadbent T, Hsieh E, and Verkman AS. Prevention of toxin-induced intestinal ion and fluid secretion by a small-molecule CFTR inhibitor. Gastroenterology 126: 511-519, 2004.
25. Thiagarajah JR, Song Y, Haggie P, and Verkman AS. A small molecule CFTR inhibitor produces cystic fibrosis-like submucosal gland fluid secretions in normal airways. FASEB J 18: 875-877, 2004.
26. Wallace HL, Barker PM, and Southern KW. Nasal airway ion transport and lung function in young people with cystic fibrosis. Am J Respir Crit Care Med 168: 594-600, 2003.
27. Willumsen NJ and Boucher RC. Sodium transport and intracellular sodium activity in cultured human nasal epithelium. Am J Physiol Cell Physiol 261: C319-C331, 1991.
28. Yamaya M, Finkbeiner WE, Chun SY, and Widdicombe JH. Differentiated structure and function of cultures from human tracheal epithelium. Am J Physiol Lung Cell Mol Physiol 262: L713-L724, 1992.
29. - channels in mammalian cardiac myocytes. Circ Res 81: 101-109, 1997.
30. Zeiher BG, Eichwald E, Zabner J, Smith JJ, Puga AP, McCray PB, Caspecchi MR, Welsh MJ, and Thomas KR. A mouse model for the ΔF508 allele of cystic fibrosis. J Clin Invest 96: 2051-2064, 1995.
31. Zeitlin PL, Diener-West M, Rubenstein RC, Boyle MP, Lee CK, and Brass-Ernst L. Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. Mol Ther 6: 119-126, 2002.
32. Ziady AG, Kelley TJ, Milliken E, Ferkol T, and Davis PB. Functional evidence of CFTR gene transfer in nasal epithelium of cystic fibrosis mice in vivo following luminal application of DNA complexes targeted to the serpin-enzyme complex receptor. Mol Ther 5: 413-419, 2002.